All In Biotech

Drug Trial Radar · NCT06002555

Relative Bioavailability of a New Presentation of Apraglutide Versus the Reference Formulation

A Randomized Open-label, Single Dose, 3-Period, 6-Sequence, Cross-Over Trial With Washout Periods of at Least 14 Days to Investigate the Relative Bioavailability of Apraglutide in Dual Chamber Syringes Versus the Reference Formulation in Vials Following Subcutaneous Administrations in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Oct 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

34

Actual

Start

May 23, 2023

Primary completion

Sep 22, 2023

Study completion Sep 22, 2023

Sponsor

Lead sponsor
VectivBio AGIndustry
Sponsor type
Industry
First posted
Aug 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 67 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This trial compares the relative bioavailability of apraglutide in dual-chamber syringes (DCS) versus the reference formulation apraglutide in vials.

Conditions

  • Healthy Subjects

Interventions

  • ApraglutideDrug

    Peptide analogue of GLP-2

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Plasma apraglutide primary PK parameter: Maximum observed plasma concentration (Cmax)Time frame: 0 to 312 hours post dose in each period
  2. Plasma apraglutide primary PK parameter: AUCinf or AUClastTime frame: 0 to 312 hours post dose in each period

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • ICON Clinical Research Unit

    Groningen, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.